ad

Indoco Remedies Share Price Jumps 13% in a Week: What Is Behind the Rally, Why the Q2 Profit Needs a Closer Look and Which Levels Analysts Are Watching Next

Indoco Rs 248.73 (+10.56%, 12:43 PM, 18 Nov). Up 13.3% in a week, 16.5% in two. Q2 profit Rs 19.47 cr includes Rs 36.63 cr property gain. RSI 86.6. 13.6% below 52-week high.


18 Nov 2026 • 1:01 pm

Indoco Remedies Share Price Jumps 13% in a Week: What Is Behind the Rally, Why the Q2 Profit Needs a Closer Look and Which Levels Analysts Are Watching Next

Quick Answer

Indoco Remedies traded at Rs 248.73 on the NSE at 12:43 PM on 18 November, up 10.56% on the day and about 13.3% over a week, which matches the 13% in the headline. The September quarter did mark a return to profit, with Rs 19.47 crore against a year-ago loss, but that figure includes a Rs 36.63 crore gain from selling a Mumbai property, so the operating picture is thinner than the headline suggests. Volume jumped to about 19 million shares against roughly 42,000 the day before, and the daily RSI of 86.6 sits deep in overbought territory. Analysts quoted in the coverage see resistance at Rs 256 to Rs 260 and support at Rs 230 to Rs 235.

Indoco Remedies share price has jumped to about Rs 249, a gain of roughly 13% in a week and 16.5% in two, and the pharma small cap is now back near Rs 256, the intraday high it hit on 15 October before sliding.

This article separates what the numbers show from what the headline implies. It reconciles the 13% and 16% claims with exchange prices, tests the Q2 profit for one-off gains, checks valuation at the live price and maps the levels analysts are watching. We found no company announcement dated 18 November that explains the move.

Click Here – Get Free Investment Predictions

What Moved the Stock on 18 November: Price, Volume and Order Book

Measure Reading
Price Rs 248.73 (NSE, 12:43 PM)
Day change Up 10.56% from the previous close of Rs 224.98
Day range Rs 225.00 to Rs 254.00, with the open at Rs 225.00 and the low at Rs 224.99
Volume 18.97 million shares, against 41,972 on 17 November, about 450 times (our arithmetic)
Pending orders 3.08 million to buy against 1.10 million to sell, about 2.8 to 1
One-week gain (our arithmetic) 13.3%, from the 11 November close of Rs 219.51
Two-week gain (our arithmetic) 16.5%, from the 4 November close of Rs 213.43

Both claims in the headline hold up against exchange prices. The stock opened at Rs 225.00 and never traded meaningfully below that, so buying was present from the first trade. Pending buy orders were nearly three times pending sell orders at midday. Delivery volumes, when published, help show whether the buying in Indoco's stock is lasting. Sizing a position for INDOCO stock with the average range in mind helps manage risk.

We found no company announcement dated 18 November that explains the surge. The volume is more than ten times the 1.65 million shares of 15 October and the 1.79 million of 27 October, the two previous spikes, so the move is unusually heavy for this stock and the cause is unconfirmed. Anyone following Indoco Remedies shares should wait for the next quarterly filing to see how much profit comes from operations. Exceptional gains rarely repeat, so a view on Indoco's stock should rest on the underlying business. Retail interest can magnify swings in INDOCO stock when volumes jump from thousands to millions.

Q2 FY27 Profit: A Real Turnaround or a Property Gain?

Item Reading Note
Consolidated revenue Rs 506.92 crore Up 7.4% from Rs 471.83 crore, and the first quarter above Rs 500 crore
Net profit Rs 19.47 crore Against a loss of Rs 9.21 crore a year earlier
Profit before tax Rs 24.19 crore After exceptional items
Exceptional gain Rs 36.63 crore Sale of a property in Andheri East, Mumbai
Result without that gain (our arithmetic) Loss before tax of about Rs 12.44 crore Rs 24.19 crore less Rs 36.63 crore, with tax not adjusted
First-half net profit Rs 84.92 crore Against a loss of Rs 45.55 crore

Revenue growth of 7.4% is real, and so is the return to a positive bottom line. The profit, however, would have been a loss without the property sale, so the headline about a return to quarterly profitability describes the reported number and not the operating business. Another wire report put profit at Rs 18.4 crore, and we use Rs 19.47 crore, which several reports cite, so check the exchange filing as the final word. A pullback toward the 50-day average would be a normal test for Indoco Remedies stock. Sensible investors treat headlines about Indoco Remedies shares as a prompt to check the data, not a reason to act.

The market also did not cheer the result at the time. The stock closed at Rs 220.65 on results day, 27 October, and slid to Rs 208.30 by 30 October, a fall of 5.6% in three sessions (our arithmetic). That makes a surge three weeks later harder to link to the profit news. For INDOCO stock, a stretched RSI is a caution flag and not a sell signal. Regulatory inspections and approvals are recurring catalysts for pharma names such as Indoco Remedies stock. The 52-week range gives context to any price level in Indoco Remedies shares.

Screen pharma stocks with the Univest Screener

Valuation Check at the Live Price

Measure Reading
Price Rs 248.73
Trailing earnings per share Rs 3.44
Price to earnings (our arithmetic at the live price) About 72.3, against an industry multiple of 40.12 at the previous close
Book value per share Rs 110.65, so price to book is about 2.25
Return on equity -7.71%
Debt to equity 1.04
Market capitalisation (our arithmetic) About Rs 2,292 crore, against Rs 2,073 crore at the previous close
Dividend yield 0.09%

Trailing earnings include the property gain, so the multiple of about 72 flatters the company's earning power and still looks expensive against the industry. A negative return on equity and a debt to equity ratio just above one add to the case for caution. Comparing Indoco Remedies stock with larger drugmakers shows how much more volatile a small cap can be. Interest cost matters for Indoco Remedies shares given a debt to equity ratio near one.

Valuation does not stop a small cap from running when volumes surge. It does mean the price now depends on future earnings that have not yet been reported, and a price to book above two for a loss-making return on equity is a premium that needs growth to justify it. Operating profit, not reported profit, is the better yardstick for judging INDOCO stock. A return to profit is a positive step, and its quality is the issue in Indoco Remedies stock.

Indoco Remedies Share Price Levels: Resistance Near Rs 256 and Support Near Rs 230

Level Why it matters
Rs 280 to Rs 288 Breakout zone analysts cite, next to the 52-week high of Rs 287.80
Rs 256 to Rs 260 Resistance zone, with the 15 October intraday high at Rs 256.50
Rs 248.73 Live price at 12:43 PM
Rs 236.15 50-day average, about 5.2% below the price
Rs 230 to Rs 235 Support zone, near the 14 October close of Rs 234.35 and the 21 October close of Rs 231.50
Rs 205.10 Low of 30 October, the lowest in the past six weeks
Rs 162.19 52-week low

The daily RSI is 86.6, far above the 70 mark that traders treat as overbought. That reading signals a stretched move and gives no direction on its own, since stretched moves can pause, retrace toward the average or run further on fresh volume. The average true range is Rs 7.72, about 3.1% of the price. Check the exchange announcements page for any news that explains the move in Indoco Remedies shares. Past performance in Indoco's stock does not predict the next move.

A close above Rs 260 on strong volume would open the road toward the Rs 280 to Rs 288 zone, while a slip below Rs 230 would erase the week's gain. At Rs 248.73 the stock is 13.6% below its 52-week high and 53.4% above its low (our arithmetic). The one-week gain in INDOCO stock is a fact, and whether it holds is a separate question. Compare the day's gain with the sector index to see how much of Indoco Remedies stock is stock specific.

Risks and What to Track Before Acting

Risk or marker Why it matters
Dependence on one-off gains Reported profit relied on the property sale, so operating profit is the number to watch next quarter
Thin trading history Volume in the five sessions before today ranged from 41,972 to 252,516 shares, so exits can be hard in a fall
Price band The band allows a move of 20% either way, up to about Rs 270, so daily swings can be large
Debt to equity of 1.04 Borrowings leave less room if growth slows
Sector direction The Nifty Pharma index and large peers such as Cipla show how the wider sector is moving

A stock that moves 10% in a morning can move back just as quickly, and the best check is whether volume stays high on the next two sessions. Compare the day's gain with the Nifty 50 to see how much is stock specific. Univest does not give buy or sell calls, and this article is general information. Size any position to your own risk limits. A pharma company with an overseas arm and domestic brands gives Indoco Remedies shares several moving parts to follow. Time horizon matters for Indoco's stock, since swing traders and long-term investors read the same chart differently.

Download the Univest iOS App or Univest Android App to track Indoco and set price alerts.

Conclusion

Indoco Remedies trades near Rs 249 after a 13.3% gain in a week and a 10.56% jump today on heavy volume. The Q2 profit of Rs 19.47 crore is a genuine turnaround on paper, yet it rests on a Rs 36.63 crore property gain, and the stock now trades near 72 times trailing earnings. Small caps with thin history can gap on news, so position size matters in Indoco's stock. A rally that starts on one session of heavy volume needs follow-through to be convincing in INDOCO stock.

Analysts see Rs 256 to Rs 260 as the ceiling to clear and Rs 230 to Rs 235 as the floor. With the RSI at 86.6, the next two sessions will show whether the volume is the start of a trend or a one-day burst. Heavy volume on a single day can reverse quickly, as past spikes in Indoco Remedies stock on 15 and 27 October showed. The price band limits how far Indoco Remedies shares can move in one session, though 20% is still wide. Write down your own entry, exit and risk limits before trading Indoco's stock.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

Why is Indoco Remedies stock rising today?

Ans. The stock is up 10.56% at Rs 248.73 on volume of about 19 million shares, roughly 450 times the previous day. We found no company announcement dated 18 November. Coverage points to improving technical momentum and the return to quarterly profit, though the specific trigger is unconfirmed.

Is the 13% weekly gain in Indoco Remedies correct?

Ans. Yes. At Rs 248.73 the stock is up about 13.3% from the 11 November close of Rs 219.51, and about 16.5% from the 4 November close of Rs 213.43, which matches the two-week figure in the coverage. The 10.56% figure refers to today's move only.

Did Indoco Remedies really return to profit in Q2 FY27?

Ans. On the reported numbers, yes: net profit was Rs 19.47 crore against a loss of Rs 9.21 crore a year earlier. That figure includes a Rs 36.63 crore exceptional gain from a Mumbai property sale, and profit before tax would have been a loss of about Rs 12.4 crore without it.

Is Indoco Remedies share expensive after the jump?

Ans. At Rs 248.73 the price to earnings multiple is about 72 on trailing earnings per share of Rs 3.44, against an industry multiple near 40, and price to book is about 2.25. Trailing earnings include the property gain, so the multiple understates how stretched the valuation is.

What are the key resistance and support levels for INDOCO stock?

Ans. Analysts quoted in the coverage see resistance at Rs 256 to Rs 260 and support at Rs 230 to Rs 235, with a breakout opening Rs 280 to Rs 288. Our price data agrees: the 15 October high was Rs 256.50 and the 52-week high is Rs 287.80.

Is the Indoco Remedies chart overbought?

Ans. The daily RSI is 86.6, well above the 70 level that traders treat as overbought, and the price is about 5.2% above its 50-day average of Rs 236.15. That signals a stretched move, which can pause, pull back or continue, so the indicator alone gives no direction.

What are the main risks in Indoco Remedies shares?

Ans. Profit depends on a one-time gain, trailing valuation is high, return on equity is negative and debt to equity is 1.04. Trading volume was only tens of thousands of shares a day before this surge, so exits can be difficult, and the price band allows 20% daily swings.

Should I buy Indoco Remedies shares after the rally?

Ans. Univest does not give buy or sell calls. The company has returned to a reported profit and the chart is strong, but the profit rests on a property sale, valuation is high and the move is stretched. Read the filings, consider staggered entries and keep any position within your own risk limits.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down